Search results

598 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375) [ID2710]

In development [GID-TA10586] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

In development [GID-TA10305] Expected publication date: 31 March 2021

Type

Technology appraisal guidance

Status

In development
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535

In development [GID-TA10412] Expected publication date: 13 January 2021

Type

Technology appraisal guidance

Status

In development
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

In development [GID-TA10334] Expected publication date: 24 March 2021

Type

Technology appraisal guidance

Status

In development
Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: 03 February 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]

In development [GID-TA10485] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]

In development [GID-TA10670] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
AR101 for treating peanut allergy [ID1282]

In development [GID-TA10713] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]

In development [GID-TA10551] Expected publication date: 10 February 2021

Type

Technology appraisal guidance

Status

In development
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]

In development [GID-TA10651] Expected publication date: 02 February 2022

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: 10 March 2021

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Cenobamate for focal onset seizures in epilepsy [ID1553]

In development [GID-TA10661] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating beta-thalassaemia ID1554

In development [GID-TA10506] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - everolimus [ID117]

In development [GID-TAG241] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development